Rpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives

Similar documents
Omeprazole 10mg. Name, Restriction, Manner of administration and form OMEPRAZOLE omeprazole 10 mg enteric tablet, 30 (8332M) Max. Qty.

Rpts. GENERAL General Schedule (Code GE)

Proton Pump Inhibitors (PPIs) (Sherwood Employer Group)

High use of maintenance therapy after triple therapy regimes in Ireland

Proton Pump Inhibitors

Proton Pump Inhibitors. Description

Drug Class Monograph

PRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW

Proton Pump Inhibitors Drug Class Prior Authorization Protocol

Proton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014

Measuring and Evaluating Indicators of Appropriate Prescribing in Older. Populations

European Medicines Agency decision

GASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali

MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)

Proton Pump Inhibitor De-prescribing Guidance

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Public Assessment Report. Scientific discussion. Rabeprazolnatrium Torrent Pharma. 10 mg and 20 mg gastro-resistant tablets. Rabeprazole sodium

Setting The setting was primary care. The economic analysis was conducted in Glasgow, UK.

Appropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist

Developing Evidence-Based Best Practices for the Prescribing and Use of Proton Pump Inhibitors in Canada

COMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées

PPIs: Good or Bad? 1. Basics of PPIs. Gastric Acid Basics. Outline. Gastric Acid Basics. Proton Pump Inhibitors (PPI)

EU RISK MANAGEMENT PLAN (EU RMP)

See Important Reminder at the end of this policy for important regulatory and legal information.

Nexium 24HR. Tools and information for you and your pharmacy team NOW OTC FOR FREQUENT HEARTBURN. Consumer Healthcare Pfizer Inc.

All Indiana Medicaid Prescribers and Pharmacy Providers

OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF LOSEC AND ASSOCIATED NAMES (SEE ANNEX I)

Committee Approval Date: October 14, 2014 Next Review Date: October 2015

Patient advice regarding long term use of Proton Pump Inhibitors (PPIs)

Pharmacoeconomic analysis of proton pump inhibitor therapy and interventions to control Helicobacter pylori infection Klok, Rogier Martijn

Review article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors

The usual dose is 40 mg daily with amoxycillin 1.5 g (750 mg b.d.) for 2 weeks. Up to 2 g/day of amoxycillin has been used in clinical trials.

Prevpac Pylera Omeclamox-Pak

Gastro-oesophageal reflux disease and peptic ulcer disease. By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D

KK College of Nursing Peptic Ulcer Badil D ass Dass, Lecturer 25th July, 2011

RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets

NOXICID CAPS Esomeprazole (as magnesium) PRODUCT INFORMATION

A. Incorrect! Histamine is a secretagogue for stomach acid, but this is not the only correct answer.

Study population The study population comprised hypothetical patients with gastric and duodenal ulcer.

Drug Class Review on Proton Pump Inhibitors

Peptic ulcer disease Disorders of the esophagus

Difference between omeprazole and omeprazole delayed release

Some H2 Antihistaminics And Ppi-S Products Authorized In Albania And Their Availability For Pediatric Groups

Management of dyspepsia and of Helicobacter pylori infection

Management of Dyspepsia

AstraZeneca and Daiichi Sankyo Launch Proton Pump Inhibitor Nexium 10 mg and 20 mg Granules for Suspension, Sachet, in Japan

This PDF is available for free download from a site hosted by Medknow Publications

H o w d o e a c t. y o u r a c i

Drug Class Review Proton Pump Inhibitors

Clinical guideline Published: 3 September 2014 nice.org.uk/guidance/cg184

Drug Class Review on Proton Pump Inhibitors

The Appropriateness of Acid Suppressive Medications Use in a Tertiary Hospital in Kedah

Internal Clinical Guidelines Team

Setting The setting was community. The economic study was carried out in the USA.

Zantac for stomach ulcers

QUICK QUERIES. Topical Questions, Sound Answers

Concise guide to management of reflux disease in primary care

COMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées

ASSESSMENT OF THE PAEDIATRIC NEEDS GASTRO-ENTEROLOGY DISCLAIMER

PATIENT INFORMATION LEAFLET PEPLOC RANGE

Policy Evaluation: Proton Pump Inhibitors (PPIs)

Setting The setting was secondary care. The economic study was carried out in Hong Kong, China.

Package leaflet: Information for the user. Omeprazol STADA 20 mg gastro-resistant tablets Omeprazole

Helicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35.

long term use Nexium Nexium

ALL WALES PROTON PUMP INHIBITOR AND DYSPEPSIA RESOURCE PACK MATERIAL TO SUPPORT APPROPRIATE PRESCRIBING OF PROTON PUMP INHIBITORS ACROSS WALES

Survey on repeat prescribing for acid suppression drugs in primary care in Cornwall and the Isles of Scilly

CYP2C19-Proton Pump Inhibitors

Package leaflet: Information for the user. PARIET 10 mg and 20 mg gastro-resistant tablets Rabeprazole sodium

II. Angiotensin Receptor Blockers (ARBs) Drug Class Review

EMILOK Global. (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated

Package leaflet: Information for the patient. Rabeprazole 20 mg Gastro-resistant Tablets. (rabeprazole sodium)

Patient Satisfaction with Proton-pump Inhibitors in a Tertiary Care Teaching Hospital

Patient information. Laryngopharyngeal Reflux ( LPR) Ear Nose and Throat Directorate PIF 1423/V4

Proton Pump Inhibitor Clinical Trials: Focus On Lansoprazole In The Treatment Of Gastroesophageal Reflux Disease And Frequent Heartburn

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. lansoprazole delayed-release capsule (Manufacturer s standard)

Step Therapy Approval Criteria

Study population The study population comprised a hypothetical cohort of patients with confirmed reflux oesophagitis.

Class Update: Proton Pump Inhibitors and Histamine 2 Receptor Antagonists

Losamel 20mg Gastro-resistant Tablets

Summary of Findings on the Prescribing and Use of Proton Pump Inhibitors. COMPUS Interim Report CCOHTA. March 6, 2006

Applicant Invented name Strength Pharmaceutical Form Route of administration HEXAL AG Industriestraße 25 D Holzkirchen.

TEXAS VENDOR DRUG PROGRAM

COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION

ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANTS IN THE MEMBER STATES

Management of dyspepsia in adults in primary care

Disclosures. Proton Pump Inhibitors Deprescribing? Deprescribing PPI Objectives. Deprescribing. Proton Pump Inhibitors (PPI) 5/28/2018.

PACKAGE LEAFLET: INFORMATION FOR THE USER. Losec 10 mg hard capsules Losec 20 mg hard capsules Losec 40 mg hard capsules Omeprazole

How Rabeprazole Sandoz works

Source of effectiveness data The effectiveness data were derived from a review and synthesis of completed studies.

Oral proton pump inhibitors (PPIs)

Package leaflet: Information for the patient

GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA

A C A D E M I C D E TA I L I N G C H O O S I N G W I S E LY C O N F E R E N C E O C T 2 1, PA M M C L E A N - V E Y S E Y B S C P H A R M D R

COMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées. Proton Pump Inhibitor Project Overview: Summaries

Identifying patients who may benefit from stepping down PPI treatment

Package leaflet: Information for the user. Ulcerbrex 20 mg gastro-resistant tablets Rabeprazole sodium

Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease where next?

PACKAGE INSERT. 10mg: Each enteric-coated delayed release tablet contains 10 mg of rabeprazole sodium, equivalent

Transcription:

Esomeprazole 20mg Name, Restriction, Manner of esomeprazole 20 mg enteric tablet, 30 (8886Q) (029W) Gastric ulcer Peptic ulcer Treatment Phase: Initial treatment The therapy must be for initial treatment of a peptic ulcer, in a patient testing negative for helicobacter pylori infection OR The patient must have failed treatment with helicobacter pylori eradication therapy

Helicobacter pylori eradication therapy should be considered. Low-dose proton pump inhibitors are appropriate step-down therapy A low- dose proton pump inhibitor includes: lansoprazole mg, omeprazole 0mg, pantoprazole 20mg and rabeprazole 0mg No increase in the maximum quantity or number of units may be No increase in the maximum number of repeats may be authorised

Name, Restriction, Manner of esomeprazole 20 mg enteric tablet, 30 (8600P) (0343J) Scleroderma oesophagus Low dose proton pump inhibitors are appropriate step-down therapy A low dose proton pump inhibitor includes: lansoprazole mg, omeprazole 0mg, pantoprazole 20mg and rabeprazole 0mg No increase in the maximum quantity or number of units may be authorised

Name, Restriction, Manner of esomeprazole 20 mg enteric tablet, 30 (8600P) (0343J) Pathological hypersecretory conditions including Zollinger-Ellison syndrome and idiopathic hypersecretion Low dose proton pump inhibitors are appropriate step-down therapy A low dose proton pump inhibitor includes: lansoprazole mg, omeprazole 0mg, pantoprazole 20mg and rabeprazole 0mg No increase in the maximum quantity or number of units may be authorised

Name, Restriction, Manner of esomeprazole 20 mg enteric tablet, 30 (8600P) (0343J) Gastro-oesophageal reflux disease The treatment must be for maintenance therapy AND The condition must be healed The treatment must be maintenance therapy for erosive reflux oesophagitis AND The condition must have been previously diagnosed by endoscopy Low dose proton pump inhibitors are appropriate step-down therapy A low dose proton pump inhibitor includes: lansoprazole mg, omeprazole 0mg, pantoprazole 20mg and rabeprazole 0mg No increase in the maximum quantity or number of repeats

Name, Restriction, Manner of esomeprazole 20 mg enteric tablet, 30 (New) (New) Gastro-oesophageal reflux disease The treatment must be for initial treatment of symptomatic gastrooesophageal reflux disease OR The treatment must be for the short-term maintenance of gastrooesophageal reflux disease Low dose proton pump inhibitors are appropriate step-down therapy A low dose proton pump inhibitor includes: lansoprazole mg, omeprazole 0mg, pantoprazole 20mg and rabeprazole 0mg

Esomeprazole 40mg Name, Restriction, Manner of esomeprazole 40 mg enteric tablet, 30 (340B) esomeprazole 40 mg capsule, 30 (033R) Pathological hypersecretory conditions including Zollinger-Ellison syndrome and idiopathic hypersecretion Patients symptoms must be inadequately controlled using a standard dose proton pump inhibitor. Pharmaceutical benefits that have the form esomeprazole tablet 40 capsule 40 mg are equivalent for the purposes of substitution. Continuing Therapy Only: For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory s for Nurse Practitioners. A standard dose proton pump inhibitor includes: esomeprazole 20mg, lansoprazole 30mg, omeprazole 20mg, pantoprazole 40mg, rabeprazole 20mg

Name, Restriction, Manner of esomeprazole 40 mg enteric tablet, 30 (340B) esomeprazole 40 mg capsule, 30 (033R) Scleroderma oesophagus Patients symptoms must be inadequately controlled using a standard dose proton pump inhibitor. Pharmaceutical benefits that have the form esomeprazole tablet 40 capsule 40 mg are equivalent for the purposes of substitution. Continuing Therapy Only: For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory s for Nurse Practitioners. A standard dose proton pump inhibitor includes: esomeprazole 20mg, lansoprazole 30mg, omeprazole 20mg, pantoprazole 40mg, rabeprazole 20mg

Name, Restriction, Manner of esomeprazole 40 mg enteric tablet, 30 (860Q) esomeprazole 40 mg capsule, 30 (0330Q) Gastro-oesophageal reflux disease Treatment Phase: Initial treatment The treatment must be for the healing of gastro-oesophageal reflux disease The treatment must be for the initial treatment of erosive reflux oesophagitis AND The condition must be proven by endoscopy Pharmaceutical benefits that have the form esomeprazole tablet 40 mg and pharmaceutical benefits that have the form esomeprazole capsule 40 mg are equivalent for the purposes of substitution. No increase in the maximum quantity or number of units may be authorised No increase in the maximum number of repeats may be authorised authorised